Industry News
Select Vaccines reports promising results for hep C
Select Vaccines reports promising results for hep C [ + ]
Microchips for in vitro diagnostics
DiagnoSwiss and bioMerieux have signed an exclusive licence agreement for the development and use of DiagnoSwiss electrochemical microchips in human in vitro diagnostics.
[ + ]Apollo starts psoriasis trial
Sydney-based biopharma Apollo Life Sciences (ASX:AOP) has commenced its phase Ib clinical trial for a topical psoriasis treatment, developed from human-expressed protein. [ + ]
LCT files for pre-IND meeting with FDA
Living Cell Technologies (ASX:LCT) has filed a request for a pre-IND meeting with the US FDA to seek guidance and feedback on the development program for its NeurotrophinCell (NtCell) product for the treatment of Huntington's disease. [ + ]
In brief: MediVac, C3, Premier Bionics
Bob Atwill will join MediVac (ASX:MDV) as a consultant to assist in the commercialisation of the company's MetaMizer series II. Atwill was formerly sales and marketing director of London Stock Exchange listed orthopaedic company Corin Group. [ + ]
Metabolic commences phase IIb obesity drug trial
Melbourne-based Metabolic Pharmaceuticals (ASX:MBP) has started recruiting subjects in a low dose phase IIb clinical trial of its obesity drug AOD9604. [ + ]
Investment to develop pain therapy
A pain drug development company spun out of The University of Queensland has received a $3.25 million investment commitment to develop its innovative pain therapy.
[ + ]Resolution in sight for Ventracor and HeartWare legal dispute
Ventracor (ASX:VCR) and HeartWare (ASX:HTW) have commenced negotiations to settle an on-going patent dispute between the two artificial heart firms. [ + ]
Premier Bionics plans AIM listing
Premier Bionics (ASX:PBI) is seeking to list on London's Alternative Investment Market (AIM). [ + ]
Epitan raises AUD$6.9 m, plans AIM listing
Melbourne-based Epitan (ASX:EPT, ADR:EPTNY, XETRA:UR9) has raised AUD$6.9 million before costs via a private placement to institutional and private investors and will once again seek to list on London's AIM stock market. [ + ]
In brief: Australian Stem Cell Centre, Biotech Capital, Circadian, Alexanders Securities
Prof Vicki Sara has been appointed as director of the Australian Stem Cell Centre and will replace inaugural chairman Robert Moses when he relinquishes the role he has held for three years at the Annual General Meeting (AGM) on November 22. Sara is the chancellor of the University of Technology, Sydney, a fellow of the Australian Academy of Technological Science and Engineering and a former head of the Australian Research Council. [ + ]
New gene shows way for autoimmune disease
A new gene suspected to contribute to autoimmune diseases such as type 1 diabetes and lupus has been discovered by ANU immunologists.
[ + ]Panvax signs agreement with US institute to develop malaria vaccine
Melbourne's Austin Research Institute (ARI) and vaccine developer Panvax have signed an agreement with the Walter Reed Army Institute of Research to develop an experimental malaria vaccine. [ + ]
Acrux's US partner completes enrolment for phase III trial
Melbourne-based Acrux's (ASX:ACR) US partner Vivus (NASDAQ:VVUS) has completed enrolment for its phase III clinical study of Acrux's estradiol transdermal spray product Evamist for the treatment of menopausal symptoms. [ + ]
Phylogica signs licensing deal, collaborates with UWA
Phylogica (ASX:PYC) has signed a licensing deal with Massachusetts General Hospital and Johns Hopkins University to give the Perth-based company access to a new genetic screening technology. [ + ]
